Skip to main content

Skin Lesions

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Orlucent
OrlucentCA - Los Gatos
1 program
Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.N/A1 trial
Active Trials
NCT02009085Completed126Est. Jun 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OrlucentPilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.

Clinical Trials (1)

Total enrollment: 126 patients across 1 trials

NCT02009085OrlucentPilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.

Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.

Start: Jun 2013Est. completion: Jun 2017126 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.